Khang & Khang LLP announces that it is investigating claims against Regulus Therapeutics Inc. concerning possible violations of federal securities laws. If you purchased shares of Regulus, and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, On June 27, 2016, the Company confirmed that it was contacted by the U.S. Food and Drug Administraion that its new drug to treat the chronic hepatitis C virus infection will be put on clinical hold due to a second incidence of jaundice.